International Journal of Sciences: Basic and Applied Research
Abstract
Breast carcinoma is the most frequently cancer in women (24%) and the main cause of cancer death in women worldwide. Based on data from globocan 2018 shows the incidence of breast cancer is around 2.08 million (11.6%) which is the second rank of all cancers after lung cancer with a mortality rate of 626.6 thousand (6.6%). However, prognosis of the breast carcinoma is influenced by several factors, including tumor histology grade and Tumor Infiltrating Lymphocytes (TILs). PD-L1 expression has been investigated as a potential biomarker and immune checkpoint to assess the response of various types of cancer. This study aims to determine PD-L1 expression in Invasive Breast Carcinoma of No Special Type (IBC-NST) grades 1,2 and 3. This study used a sample of 80 cases of paraffin block for IBC-NST patients from 2017 to 2020. There were 17 samples (21.3%) with grade 1, 32 samples (40%) with grade 2, and 31 samples (38.8%) with grade 3. The number of samples with positive PD-L1 expression were 63 samples, and 17 samples of negative PDL-1 expression were obtained. In the PD-L1 negative group, from a total of 17 samples, 4 samples were grade 1, 10 samples were grade 2, and 3 samples were grade 3. In the PD-L1 positive group, from a total of 63 samples, 13 samples with grade 1, 22 with grade 2, and 28 samples with grade 3. Based on the Chi-square test, p value = 0.115 (p > 0.05). The proportion of PD-L1 expression was higher at higher grades. There was no significant difference in PD-L1 expression in IBC-NST grade 1, grade 2 and grade 3
